Is the outlined management plan appropriate for a 75-year-old male with major depressive disorder, type 2 diabetes, untreated obstructive sleep apnea, passive suicidal ideation, and current medications (modafinil, bupropion, brexpiprazole, vilazodone), and what are your recommendations regarding the medication adjustments?

Assessment of the Management Plan

The plan has significant concerns that require modification, particularly regarding the use of modafinil as primary treatment for depression-related symptoms and the discontinuation of Rexulti without adequate safety monitoring in a patient with passive suicidal ideation.

Critical Safety Issues

Passive Suicidal Ideation Management

This 75-year-old patient presents with passive suicidal ideation, depressed mood, anhedonia, and poor sleep—all requiring immediate and appropriate antidepressant management. The decision to discontinue Rexulti (brexpiprazole) due to "prolonged non-adherence" is problematic when the patient is currently experiencing passive suicidal ideation 1. While providing the 988 crisis line is appropriate, this alone is insufficient for a patient with active suicidal thoughts.

The plan lacks:

• Specific safety assessment intervals
• Clear criteria for when to escalate care
• Family/caregiver involvement in safety planning
• Concrete follow-up timeline (4 weeks is too long for someone with suicidal ideation)

Medication Strategy Concerns

Using modafinil as the primary intervention for what appears to be major depressive disorder is not evidence-based and potentially harmful. 2, 3. The American College of Physicians guidelines clearly recommend either cognitive behavioral therapy or second-generation antidepressants as first-line treatment for major depressive disorder 2.

Modafinil's role in depression is limited to adjunctive therapy for residual fatigue in patients already on adequate antidepressant treatment 4. The meta-analysis by Goss et al. (2013) showed modafinil works as augmentation therapy (effect size -0.35), not as primary treatment 4. More concerning, one study found 2 patients developed new-onset or worsening suicidal ideation with modafinil added early in treatment, leading to premature trial discontinuation 5.

Appropriate Management Recommendations

Immediate Actions (Within 1 Week)

Restart or optimize antidepressant therapy immediately:

• Continue Wellbutrin 150 mg daily as planned, but consider increasing to 300 mg daily after 1-2 weeks if tolerated
• For a 75-year-old with depression, preferred agents include citalopram, escitalopram, or sertraline 6, 7
• Avoid paroxetine and fluoxetine in older adults due to higher adverse effect rates 6

Regarding Rexulti discontinuation:

• If the patient was previously adherent and responded to Rexulti, consider restarting at low dose (0.5-1 mg) given the current passive suicidal ideation 1
• Brexpiprazole is FDA-approved for adjunctive treatment of major depressive disorder and showed efficacy in patients with incomplete response to antidepressants 8
• If discontinuing, taper gradually rather than abrupt cessation

Safety monitoring:

• Schedule follow-up within 1-2 weeks, not 4 weeks
• Involve family/caregiver in safety planning
• Provide written safety plan with specific warning signs and actions
• Document specific suicidal ideation assessment (frequency, intensity, plan, intent, access to means)

Sleep Apnea Management

The emphasis on treating sleep apnea is appropriate, but the timeline and approach need adjustment:

• Refer to sleep medicine or primary care for Inspire device evaluation immediately
• Consider interim CPAP trial if Inspire evaluation will be delayed
• The relationship between OSA and depression is bidirectional—treating both simultaneously is essential 9

Hold modafinil until:

1. Sleep apnea is adequately treated (CPAP compliance or Inspire device)
2. Patient is on therapeutic dose of antidepressant for 4-6 weeks
3. Residual fatigue persists despite depression improvement
4. Patient is psychiatrically stable without suicidal ideation

If modafinil is eventually used, start at 100 mg daily (not "half dose"—be specific) and increase to 200 mg after 1 week if needed 4, 10.

Diabetes Management Integration

Nocturia from type 2 diabetes is disrupting sleep—coordinate with primary care:

• Optimize diabetes control (target HbA1c around 8% for a 75-year-old with comorbidities is reasonable) 11
• Review timing of diabetes medications
• Assess for fluid management strategies to reduce nocturia
• Consider nephrology referral if creatinine clearance <60 mL/min, as this affects both diabetes management and psychiatric medication dosing 11, 1

Psychosocial Interventions

The "four-pillar approach" discussion is good, but needs concrete implementation:

• Refer for cognitive behavioral therapy or problem-solving therapy 2, 7
• Increase AA meeting attendance or add depression-specific support groups
• Address social isolation with specific interventions (senior center, volunteer activities, structured socialization)
• Consider care coordination/case management given multiple comorbidities 12

Medication Adherence Strategy

The plan mentions "counseling on medication adherence" but provides no concrete strategy:

• Identify specific barriers (cost, side effects, forgetfulness, beliefs about medication)
• Consider pill organizers, medication reminders, or simplified regimen
• Involve pharmacy for medication synchronization
• Schedule medication review visits separate from therapy sessions

Revised Follow-Up Timeline

• Week 1-2: Safety check (phone or in-person), assess suicidal ideation, medication tolerability
• Week 4: Full psychiatric evaluation, assess depression response, adjust medications as needed
• Week 8: Reassess depression symptoms, evaluate need for modafinil if residual fatigue persists
• Week 12: Determine maintenance treatment plan

Common Pitfalls to Avoid

1. Treating fatigue as the primary problem when it's a symptom of untreated major depression
2. Underestimating suicide risk in older adults with passive ideation—they have higher completion rates
3. Attributing all symptoms to sleep apnea without addressing the primary psychiatric disorder
4. Extended follow-up intervals in patients with suicidal ideation
5. Polypharmacy without clear indication—each medication should have a specific, evidence-based purpose 13

In summary: Prioritize evidence-based antidepressant treatment, ensure immediate safety with closer follow-up, defer modafinil until depression is adequately treated and sleep apnea is managed, and implement concrete psychosocial interventions rather than general discussions.